Abstract | OBJECTIVES: METHODS: RESULTS: At a median follow-up of over 28 months, clinically meaningful improvements in PFS were noted across all groups with SVd. The median SVd PFS was longer in all subgroups ( lenalidomide-refractory: 10.2 vs. 7.1 months, PI-naïve: 29.5 vs. 9.7; bortezomib-naïve: 29.5 vs. 9.7; 1LOT: 21.0 vs. 10.7; p < .05). The lenalidomide-refractory subgroup had longer OS with SVd (26.7 vs. 18.6 months; HR 0.53; p = .015). In all subgroups, overall response and ≥very good partial response rates were higher with SVd. The manageable safety profile of SVd was similar to the overall patient population. CONCLUSIONS:
|
Authors | Maria-Victoria Mateos, Monika Engelhardt, Xavier Leleu, Mercedes Gironella Mesa, Michele Cavo, Meletios Dimopoulos, Martina Bianco, Giovanni Marino Merlo, Charles la Porte, Paul G Richardson, Philippe Moreau |
Journal | European journal of haematology
(Eur J Haematol)
(May 01 2024)
ISSN: 1600-0609 [Electronic] England |
PMID | 38693052
(Publication Type: Journal Article)
|
Copyright | © 2024 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd. |